巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Adverum Biotechnologies

    ADVM
    0.950
    0.020
    2.09%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Adverum Biotechnologies - 延遲價格・最後更新於 29/09 2:49
    最高位
    0.953
    最低位
    0.950
    開市價
    --
    前收市價
    0.970
    成交量(千)
    5.89
    成交額(百萬)
    0.02
    買入
    0.950
    賣出
    0.970
    每手股數
    --
    市值(百萬)
    94.37
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    2.520 - 0.795
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Adverum Biotechnologies
    證券代碼
    ADVM.US
    所屬板塊
    Biotechnology
    公司業務
    Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections.
    發行量
    98770349
    公司總部
    800 Saginaw Drive
    公司網址
    https://www.adverum.com
    公司電郵
    mlacy@adverum.com
    公司電話
    +1 650 659-9323
    暫無內容

    關於

    Adverum Biotechnologies(ADVM.US)所屬的行業板塊為Biotechnology。
    Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections.
    詳細公司背景可參考: https://www.adverum.com